The Food and Drug Administration issued a revised final guidance on Friday that provides updated recommendations on the use of COVID-19 convalescent plasma (CCP) related to the December 2021 emergency use authorization (EUA) for CCP.
The Food and Drug Administration revised the emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) on Dec. 28 to permit the use of high-titer CCP for treatment of COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment.
AABB recently launched a new toolkit to assist transfusion services that must register with the Food and Drug Administration for the first time because they are implementing a bacterial detection test to extend the expiration of platelets to day 6 or 7 and relabel the platelets.
Complimentary registration is available for the upcoming Science & Innovation Forum that will explore the mitigation of bacterial risk in platelets from the perspective of blood centers and transfusion services. Presented by Cerus Corporation, the program will take place at 2 p.m. ET on April 15.
The Food and Drug Administration has issued an emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) as a treatment for patients battling COVID-19. AABB has developed a new toolkit for CCP under FDA’s EUA to assist members